HC Wainwright Weighs in on Nuvectis Pharma Q1 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Nuvectis Pharma in a note issued to investors on Wednesday, February 11th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.29) for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.32) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Nuvectis Pharma in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Nuvectis Pharma Stock Down 0.5%

Shares of Nuvectis Pharma stock opened at $8.76 on Thursday. The company has a market capitalization of $232.05 million, a price-to-earnings ratio of -6.64 and a beta of -0.29. The stock’s 50-day simple moving average is $8.18 and its 200-day simple moving average is $6.95. Nuvectis Pharma has a 52 week low of $5.55 and a 52 week high of $11.52.

Nuvectis Pharma (NASDAQ:NVCT) last issued its earnings results on Wednesday, February 11th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.05).

Hedge Funds Weigh In On Nuvectis Pharma

Several institutional investors have recently added to or reduced their stakes in NVCT. Police & Firemen s Retirement System of New Jersey bought a new stake in Nuvectis Pharma in the 2nd quarter worth approximately $28,000. Oppenheimer & Co. Inc. grew its holdings in shares of Nuvectis Pharma by 6.5% in the fourth quarter. Oppenheimer & Co. Inc. now owns 73,566 shares of the company’s stock valued at $555,000 after purchasing an additional 4,500 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Nuvectis Pharma by 15.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 44,022 shares of the company’s stock worth $332,000 after purchasing an additional 6,040 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Nuvectis Pharma by 3,398.9% during the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after purchasing an additional 6,084 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in Nuvectis Pharma by 417.2% during the second quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after purchasing an additional 6,909 shares during the last quarter. Hedge funds and other institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.